Download PDF

1. Company Snapshot

1.a. Company Description

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.


It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product.The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Show Full description

1.b. Last Insights on ALVO

Alvotech's recent performance was negatively impacted by regulatory setbacks, including a Complete Response Letter (CRL) from the FDA for its biologics license application. Investigations by law firms, including Hagens Berman and Rosen Law Firm, into potential securities claims against the company have been ongoing. The company's Q4 2025 earnings call highlighted progress on commercial launches and manufacturing initiatives. Alvotech's 2025 financial results and annual report have been published, providing insights into its growth prospects. Brokerages have set a price target of $7.60, with a "Hold" rating.

1.c. Company Highlights

2. Alvotech Accelerates Biosimilar Momentum Amid Strong Q4

Alvotech delivered a robust Q4 2025, posting $591 million in revenue—up 20% year‑over‑year—and adjusted EBITDA of $137 million, a 27% rise. The company’s EPS slipped to –$0.37 versus an estimate of –$0.006, reflecting licensing lumpy dynamics. With a forward‑looking EV/EBITDA of 30.8 and a P/E of 36.2, the market is pricing in continued margin expansion and new product launches.

Publication Date: Apr -12

📋 Highlights
  • Expanded Biosimilar Portfolio:: 30 biosimilars in development, generating over $185 million in global sales.
  • 2026 Revenue Guidance:: Projected $650–700 million in revenue with 20%+ growth and $180–220 million in adjusted EBITDA.
  • Regulatory Resubmission Timeline:: FDA application resubmissions expected Q2 2026 after addressing FDA observations from July 2025 inspection.
  • Manufacturing Expansion:: Second U.S. CMO partnership and Reykjavik facility upgrades to reduce single-site dependency.

Regulatory & Quality Improvements

Following FDA observations at the Reykjavik plant, Alvotech rolled out a comprehensive remediation program and will resubmit affected applications in Q2 2026. The company’s commitment to quality has restored confidence, with the facility remaining FDA‑approved and on‑market products continuing to ship to the U.S. and global markets.

Pipeline Expansion

With 30 biosimilar candidates—worth $185 million in projected sales—Alvotech is advancing launch plans for AVT05 (Simponi) and AVT06 (aflibercept) in 2026, while targeting a 2026 submission for an Eylea HD candidate. The pipeline strategy aligns with FDA draft guidance that trims large efficacy trials, accelerating time‑to‑market.

Commercial Partnerships

New alliances with Advanz Pharma and Dr. Reddy’s bolster the commercial footprint for Cimzia and Keytruda biosimilars. These deals unlock global sales channels and enhance technical and regulatory support, positioning Alvotech to capture market share as reference product exclusivities erode.

Manufacturing Strategy

Investments in a U.S. CMO partner and a second source site in Reykjavik diversify supply risk and increase operational flexibility. Additional drug‑substance and production suites in the Reykjavik facility expand capacity, while the acquisition of Ivers‑Lee strengthens downstream integration.

Guidance & Outlook

Alvotech projects 2026 revenues of $650–$700 million and adjusted EBITDA of $180–$220 million, driven by new launches and licensing income. The company aims for the high end of its range, targeting dual sourcing and capacity to capitalize on commercial momentum.

Competitive Landscape

First‑mover advantage remains key; Alvotech’s speed in development and IP positioning is designed to preempt rivals. In the Humira biosimilar space, the company holds a 9% U.S. share and expects continued growth as the innovator’s market share recedes.

3. NewsRoom

Card image cap

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Apr -10

Source: seekingalpha.com

Card image cap

Alvotech files Annual Report with the SEC

Mar -30

Source: globenewswire.com

Card image cap

Alvotech Publishes 2025 Annual Report

Mar -30

Source: globenewswire.com

Card image cap

Brokerages Set Alvotech (NASDAQ:ALVO) Price Target at $7.60

Mar -30

Source: defenseworld.net

Card image cap

Alvotech Q4 Earnings Call Highlights

Mar -21

Source: defenseworld.net

Card image cap

Alvotech (ALVO) Q4 2025 Earnings Call Transcript

Mar -19

Source: seekingalpha.com

Card image cap

Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar -18

Source: globenewswire.com

Card image cap

Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar -18

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.60%)

6. Segments

Biosimilar Medicines

Expected Growth: 11.6%

Alvotech's 11.6% growth in biosimilar medicines is driven by increasing demand for cost-effective alternatives to biologics, patent expirations of originator products, and growing adoption in emerging markets. Additionally, Alvotech's strong pipeline, strategic partnerships, and expanding global footprint are contributing to its rapid growth.

7. Detailed Products

Biosimilar medicines

Alvotech develops and manufactures biosimilar medicines, which are highly similar to existing biologics, offering a more affordable treatment option for patients.

Autoimmune disease treatments

Alvotech's pipeline includes biosimilars for autoimmune diseases, aiming to improve treatment outcomes and patient quality of life.

Oncology treatments

Alvotech develops biosimilars for cancer treatment, providing a cost-effective alternative to existing biologics.

Ophthalmology treatments

Alvotech's pipeline includes biosimilars for ophthalmology, focusing on treatments for age-related macular degeneration and other eye diseases.

Inflammatory bowel disease treatments

Alvotech develops biosimilars for inflammatory bowel disease, aiming to improve treatment outcomes and patient quality of life.

8. Alvotech's Porter Forces

Forces Ranking

Threat Of Substitutes

Alvotech's biosimilar products may face competition from other biosimilar manufacturers, but the company's strong R&D capabilities and partnerships with major pharmaceutical companies mitigate this threat.

Bargaining Power Of Customers

Alvotech's customers, primarily pharmaceutical companies, have limited bargaining power due to the company's unique biosimilar products and strong partnerships.

Bargaining Power Of Suppliers

Alvotech relies on a few key suppliers for raw materials and manufacturing services, but the company's strong relationships and diversified supply chain mitigate the bargaining power of suppliers.

Threat Of New Entrants

The biosimilar industry has high barriers to entry, including significant R&D investments and regulatory hurdles, making it difficult for new entrants to compete with Alvotech.

Intensity Of Rivalry

The biosimilar industry is highly competitive, with several established players competing for market share, but Alvotech's strong product pipeline and partnerships position the company for success.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 752.18%
Debt Cost 3.95%
Equity Weight -652.18%
Equity Cost 3.84%
WACC 4.66%
Leverage -115.33%

11. Quality Control: Alvotech passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Dermapharm Holding

A-Score: 5.6/10

Value: 4.6

Growth: 6.1

Quality: 5.9

Yield: 5.6

Momentum: 4.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Almirall

A-Score: 5.1/10

Value: 4.3

Growth: 2.2

Quality: 5.0

Yield: 1.9

Momentum: 9.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Sobi

A-Score: 4.8/10

Value: 2.8

Growth: 7.3

Quality: 5.5

Yield: 0.0

Momentum: 7.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Perrigo

A-Score: 4.4/10

Value: 9.4

Growth: 2.3

Quality: 4.2

Yield: 8.8

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Siegfried Holding

A-Score: 4.3/10

Value: 4.6

Growth: 7.4

Quality: 5.5

Yield: 0.6

Momentum: 0.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Alvotech

A-Score: 2.9/10

Value: 6.0

Growth: 5.6

Quality: 5.7

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.61$

Current Price

3.61$

Potential

-0.00%

Expected Cash-Flows